{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:13:29Z","timestamp":1759497209151,"version":"3.40.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lana.2024.100750","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:05:25Z","timestamp":1713870325000},"page":"100750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2\u201311 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study"],"prefix":"10.1016","volume":"34","author":[{"given":"Mar\u00eda Eugenia","family":"Toledo-Roman\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Valenzuela-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minerva","family":"Montero-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"I\u00f1iguez-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiby","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mery","family":"Mart\u00ednez-Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaldo","family":"Puga-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"German-Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsire","family":"Fern\u00e1ndez-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanet","family":"Climent-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darielys","family":"Santana-Mederos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissette","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Morales-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-9921","authenticated-orcid":false,"given":"Delaram","family":"Doroud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Vald\u00e9s-Balb\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Garc\u00eda-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Van der Stuyft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-6847","authenticated-orcid":false,"given":"Vicente","family":"V\u00e9rez-Bencomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2024.100750_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicenter cohort study","volume":"4","author":"G\u00f6tzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"year":"2023","series-title":"WHO COVID-19 dashboard","key":"10.1016\/j.lana.2024.100750_bib2"},{"key":"10.1016\/j.lana.2024.100750_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2352-4642(22)00027-X","article-title":"Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicenter observational study","volume":"6","author":"Cloete","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.lana.2024.100750_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lana.2024.100750_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.15585\/mmwr.mm7206a1","article-title":"Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 Years or younger\u2014 United States, 2023","volume":"72","author":"Wodi","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lana.2024.100750_bib7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/d41586-022-03203-8","article-title":"COVID jabs for kids: they\u2019re safe and they work \u2014 so why is uptake so patchy?","volume":"610","author":"Mallapaty","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lana.2024.100750_bib8","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2022.05.082","article-title":"Safety and immunogenicity of anti-SARS-CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: open label phase I and phase IIa clinical trials","volume":"40","author":"Toledo-Romani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.lana.2024.100750_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.medj.2022.08.001","article-title":"Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA plus vaccines: phase IIb clinical trial in adults","volume":"3","author":"Toledo-Romani","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.lana.2024.100750_bib10","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Romani","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.lana.2024.100750_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijid.2022.11.016","article-title":"Open-label phase I\/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children","volume":"126","author":"Puga-G\u00f3mez","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.lana.2024.100750_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lana.2024.100750_bib14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lana.2024.100750_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lana.2024.100750_bib16","first-page":"e64","article-title":"Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: a systematic review and meta-analysis","volume":"86","author":"Li","year":"2023","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.lana.2024.100750_bib17","article-title":"Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis","volume":"23","author":"Watanabe","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.lana.2024.100750_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.lana.2024.100750_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.lana.2024.100750_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(22)00100-X","article-title":"Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial","volume":"10","author":"Ochoa-Azze","year":"2022","journal-title":"Lancet Respir Med"},{"author":"Portal-Miranda","key":"10.1016\/j.lana.2024.100750_bib22"},{"issue":"3-4","key":"10.1016\/j.lana.2024.100750_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.37757\/MR2022.V24.N3-4.6","article-title":"Epidemiological characterization of patients in the first eight weeks following detection of SARS-CoV-2 B.1.1.529 (omicron) variant in Cuba","volume":"24","author":"Perez-Santosa","year":"2022","journal-title":"MEDICC Rev"},{"issue":"6","key":"10.1016\/j.lana.2024.100750_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/aje\/kwz043","article-title":"Evaluating the effectiveness of vaccines using a regression discontinuity design","volume":"188","author":"Basta","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.lana.2024.100750_bib25","first-page":"939","article-title":"Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme","volume":"46","author":"Smith","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.lana.2024.100750_bib26","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ije\/dys142","article-title":"Incidence rates in dynamic populations","volume":"41","author":"Vandenbroucke","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.lana.2024.100750_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.specom.2004.02.004","article-title":"On multilevel modeling of data from repeated measures designs: a tutorial","volume":"43","author":"Quen\u00e9","year":"2004","journal-title":"Speech Commun"},{"issue":"4","key":"10.1016\/j.lana.2024.100750_bib28","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/1467-8306.00310","article-title":"Evaluation of methods for classifying epidemiological data on choropleth maps in series","volume":"92","author":"Brewer","year":"2003","journal-title":"Ann Assoc Am Geogr"},{"issue":"10","key":"10.1016\/j.lana.2024.100750_bib29","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"STROBE initiative. Strengthening the reporting of observational studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.lana.2024.100750_bib30","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc Biol Sci"},{"issue":"11","key":"10.1016\/j.lana.2024.100750_bib31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jama.2022.1206","article-title":"Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection","volume":"327","author":"Shook","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lana.2024.100750_bib32","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3389\/fimmu.2020.01640","article-title":"Children from the age of three show a developmental switch in T-cell differentiation","volume":"11","author":"Knolle","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.lana.2024.100750_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/vaccines11010087","article-title":"Safety, efficacy, and immunogenicity of varying types of COVID-19 vaccines in children younger than 18 years: an update of systematic review and meta-analysis","volume":"11","author":"Tian","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.lana.2024.100750_bib34","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lana.2024.100750_bib35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-022-01874-4","article-title":"Effectiveness of CoronaVac in children 3\u20135 years of age during the SARS-CoV-2 Omicron outbreak in Chile","volume":"28","author":"Jara","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lana.2024.100750_bib36","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1038\/s41467-022-32524-5","article-title":"Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period","volume":"13","author":"Florentino","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.lana.2024.100750_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJMoa2203209","article-title":"Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age","volume":"387","author":"Tan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lana.2024.100750_bib38","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa2210058","article-title":"Covid-19 vaccine protection among children and adolescents in Qatar","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.lana.2024.100750_bib39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1001\/jama.2022.7493","article-title":"Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance","volume":"327","author":"Fleming-Dutra","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lana.2024.100750_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(22)00578-3","article-title":"Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study","volume":"23","author":"Carazo","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.lana.2024.100750_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10327","key":"10.1016\/j.lana.2024.100750_bib42","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","article-title":"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden","volume":"399","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lana.2024.100750_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12916-023-02861-3","article-title":"Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis","volume":"21","author":"Xu","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.lana.2024.100750_bib44","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3390\/vaccines11111636","article-title":"Comparative immune response after vaccination with SOBERANA\u00ae 02 and SOBERANA\u00ae plus heterologous scheme and natural infection in young children","volume":"11","author":"Perez-Nicado","year":"2023","journal-title":"Vaccines"},{"issue":"7898","key":"10.1016\/j.lana.2024.100750_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lana.2024.100750_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41392-022-01142-4","article-title":"T-cell immunity: a barrier to Omicron immune evasion","volume":"7","author":"Yu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.lana.2024.100750_bib47","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.cell.2022.05.014","article-title":"Potent cross-reactive antibodies following Omicron breakthrough in vaccines","volume":"185","author":"Nutalai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.lana.2024.100750_bib48","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1002\/jmv.27927","article-title":"Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structural-based computational assessment","volume":"94","author":"Kumar","year":"2022","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.lana.2024.100750_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109968","article-title":"Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2","volume":"117","author":"Firouzabadi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.lana.2024.100750_bib50","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines","volume":"9","author":"Pichichero","year":"2013","journal-title":"Human Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.lana.2024.100750_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104739","article-title":"Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines","volume":"25","author":"Scaria","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.lana.2024.100750_bib52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/d41586-021-01898-9","article-title":"Should children get COVID vaccines? What the science says","volume":"595","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lana.2024.100750_bib53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jamapediatrics.2020.1948","article-title":"Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units","volume":"174","author":"Shekerdemian","year":"2020","journal-title":"JAMA Pediatr"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X24000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X24000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T02:54:33Z","timestamp":1718592873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X24000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":50,"alternative-id":["S2667193X24000772"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2024.100750","relation":{},"ISSN":["2667-193X"],"issn-type":[{"type":"print","value":"2667-193X"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2\u201311 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2024.100750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100750"}}